ArticleBMC medical research methodology2025
3D IntelliGenes: AI/ML application using multi-omics data for biomarker discovery and disease prediction with multi-dimensional visualization.
Article in BMC medical research methodology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Interpreting the Black Box: Interpretable Machine Learning and Systems Pharmacology in Small-Molecule Therapeutics.Pharmaceutics · 2026Review
- Mapping the Ischemic Continuum: Dynamic Multi-Omic Biomarker and AI for Personalized Stroke Care.International journal of molecular sciences · 2026Review
- From empirical vaccinology to predictive systems-based vaccine design: multi-omics integration, artificial intelligence, and global equity challenges.Frontiers in systems biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe cutting-edge artificial intelligence (AI) and machine learning (ML) techniques have proven effective at uncovering elucidative knowledge on disease-causing biomarkers and the biological underpinnings of a plethora of human diseases. However, the high-dimensional nature of multi-omics data presents numerous challenges in its effective presentation, annotation, and interpretation. Traditional 2D visualizations often fall short in capturing the intricate relationships between multi-omics features, hindering our ability to identify meaningful correlations.
methodsIn this study, we focused on addressing such challenges by developing an innovative solution to better visualize results produced by AI/ML approaches on integrated clinical and multi-omics data for novel biomarker discovery and predictive analysis. We present an advanced version of our earlier published software with intuitive and interactive visualizations of multi-omics data in multi-dimensions i.e., 3D IntelliGenes, which offers deeper insights, most importantly by capturing greater variability in the patient data by understanding both linear and non-linear structures, evaluating AI/ML model performance, and delineating the joint impact of biomarkers on the corresponding disease states.
resultsThe overall functionality of 3D IntelliGenes is divided into two modules, data clustering and feature plotting. The data clustering module creates configurable 3D scatter plots to visualize the structure-preserving distribution of disease states, AI/ML classifier bias in the form of type I/II errors, and patient similarity through a robust density-driven clustering algorithm. Whereas the feature plotting module supports the joint analysis of pairs of multi-omics features to analyze the interdependence and discriminative power of co-expressed biomarkers.
conclusionWe report evaluated performance of 3D IntelliGenes using diverse cohorts of patients with cardiovascular and other diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.